Amy Conrad

Contatto Relazioni con gli Investitori presso TYRA BIOSCIENCES, INC.

Health Technology

Profilo

Ms. Amy Conrad is a Founder & Chief Executive Officer at Juniper Point, Inc. and a Head-Investor Relations at Tyra Biosciences, Inc. Ms. Conrad was previously employed as a Head-Investor Relations by Anadys Pharmaceuticals, Inc., a Head-Investor Relations by Bionano Genomics, Inc., and an Investor Relations & Media Contact by Regulus Therapeutics, Inc.

Posizioni attive di Amy Conrad

Società	Posizione	Inizio
TYRA BIOSCIENCES, INC.	Contatto Relazioni con gli Investitori	-
Juniper Point, Inc.	Amministratore Delegato	-

Tutte le posizioni attive di Amy Conrad

Precedenti posizioni note di Amy Conrad

Società	Posizione	Fine
REGULUS THERAPEUTICS INC.	Contatto Relazioni con gli Investitori	01/01/2016
BIONANO GENOMICS, INC.	Contatto Relazioni con gli Investitori	-
Anadys Pharmaceuticals, Inc. Anadys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Anadys Pharmaceuticals, Inc. develops and manufactures novel small molecule medicines. It engages in developing novel medicines in the areas of hepatitis C and oncology. The firm develops ANA598, a direct-acting antiviral for the treatment of hepatitis C. The company was founded by Stelios B. Papadopoulos and Kleanthis G. Xanthopoulos in 1992 and is headquartered in Little Falls, NJ.	Contatto Relazioni con gli Investitori	-

Vedi nel dettaglio l'esperienza di Amy Conrad

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Amy Conrad

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	3
BIONANO GENOMICS, INC.	Health Technology
REGULUS THERAPEUTICS INC.	Health Technology
TYRA BIOSCIENCES, INC.	Health Technology

Aziende private	2
Anadys Pharmaceuticals, Inc. Anadys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Anadys Pharmaceuticals, Inc. develops and manufactures novel small molecule medicines. It engages in developing novel medicines in the areas of hepatitis C and oncology. The firm develops ANA598, a direct-acting antiviral for the treatment of hepatitis C. The company was founded by Stelios B. Papadopoulos and Kleanthis G. Xanthopoulos in 1992 and is headquartered in Little Falls, NJ.	Health Technology
Juniper Point, Inc.